Pulmonary disease, tuberculosis

 

Zeolite increases the diffusion capacity of the lungs and shows a positive contribution with adult respiratory distress syndrome, asthma, cystic fibrosis, pulmonary emphysema, bronchopulmonary dysplasia, in COPD, and tuberculosis.

Chronic obstructive pulmonary disease (COPD) is currently the fourth most common cause of death in the world.

COPD is marked by restricted flow of oxygen in the airways that cannot be completely cured, it is progressive, advances rapidly and is associated with a strong inflammatory response of the lungs to noxious particles.

Obstructive bronchitis and pulmonary tissue damage (emphysema) act as a barrier to air flow. COPD is accompanied by long-productive cough.

It is diagnosed if symptoms are present for three months in two consecutive years, and there are no other causes of chronic cough. The disease causes scarring of the trachea and damage to lung bubbles that lose their elasticity, which interferes with the normal flow of oxygen and discharge of oxygen from the lungs. The course of disease leads to the rapid development of irreversible phase.

Results of clinical trials of lipid peroxidation in the blood of COPD patients showed that treatment with zeolite did not seem to increase lung volume, but the body's ability for rapid remission for greater resistance to relapse was increased. 

Pulmonary tuberculosis is still a dangerous disease, of which 3 million people die each year worldwide. In clinical trials, it was discovered that the use of zeolite in early diagnosis contributes to the normalization of the number and functional activity of T-lymphocytes and justifies the application of supportive zeolite therapy with tuberculosis.